Compare Novo Nordisk A/S (NVO) vs Roundhill Innov-100 0DTE Covered Call Strat ETF (QDTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Roundhill Innov-100 0DTE Covered Call Strat ETF — how do they compare? Novo Nordisk A/S trades at $44.73 (market cap $200.69B), while Roundhill Innov-100 0DTE Covered Call Strat ETF trades at $28.67. The key difference: Novo Nordisk A/S pays a 3.98% dividend while Roundhill Innov-100 0DTE Covered Call Strat ETF pays none, and Novo Nordisk A/S is trading nearer its 52-week high, Roundhill Innov-100 0DTE Covered Call Strat ETF nearer its low. Which is the better fit depends on your goals.
| NVO | QDTE | |
|---|---|---|
Market Cap | $200.69B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $63.98 | $36.60 |
52-Week Low | $35.29 | $26.85 |
Enterprise Value | $215.49B | — |
Dividend Yield | 3.98% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% today, with bearish technical signals but strong fundamentals. The stock shows robust profitability with 35.35% net margin and 59.82% ROE, supported by consistent earnings beats. Recent developments include positive pediatric obesity trial results for semaglutide and Wegovy pill launch in Germany. Cash flow remains healthy with $10.81B net inflow in 2025, though 2026 projections show a decline.
NVO presents a mixed outlook with strong fundamental metrics offset by technical weakness and competitive pressures. Investment opportunity lies in the expanding GLP-1 market and pipeline developments, while risks include market share loss to Eli Lilly and failed cardiovascular drug trials. Analyst consensus leans bullish with 57.9% buy ratings, but recent prescription slowdown concerns warrant caution.
QDTE trades at $28.86 with minimal daily movement (+0.07%). The ETF shows bearish technical signals with selling pressure outweighing buying signals 12-4. Recent news highlights concerns about the fund's sustainability as volatility declines and distributions are funded by return of capital, causing NAV erosion. The fund's 0.97% expense ratio consumes significant portions of its weekly payouts.
The outlook remains cautious given structural concerns about the fund's distribution model. While weekly income appeals to investors, the erosion of net asset value and dependence on return of capital present significant risks. Analyst sentiment has turned negative with recent downgrades citing underperformance in bull markets and unsustainable yield mechanics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Roundhill Innov-100 0DTE Covered Call Strat ETF
QDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the NASDAQ 100. It primarily holds a portfolio of U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the NASDAQ 100. This highly tactical strategy aims to maximize option premium capture by exploiting the rapid time decay of options expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on QDTE →
